JP2016511222A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511222A5 JP2016511222A5 JP2015547561A JP2015547561A JP2016511222A5 JP 2016511222 A5 JP2016511222 A5 JP 2016511222A5 JP 2015547561 A JP2015547561 A JP 2015547561A JP 2015547561 A JP2015547561 A JP 2015547561A JP 2016511222 A5 JP2016511222 A5 JP 2016511222A5
- Authority
- JP
- Japan
- Prior art keywords
- nanocarrier
- group
- acid
- compound
- subscript
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 239000002539 nanocarrier Substances 0.000 claims 33
- 239000004380 Cholic acid Substances 0.000 claims 19
- 229960002471 cholic acid Drugs 0.000 claims 19
- 239000002202 Polyethylene glycol Substances 0.000 claims 16
- 229920001223 polyethylene glycol Polymers 0.000 claims 16
- 235000019416 cholic acid Nutrition 0.000 claims 14
- 150000004032 porphyrins Chemical class 0.000 claims 14
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 13
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 13
- FDKRLXBXYZKWRZ-UWJYYQICSA-N 3-[(21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C(CC(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)O)C4=N3)O)C)C FDKRLXBXYZKWRZ-UWJYYQICSA-N 0.000 claims 12
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 239000000178 monomer Substances 0.000 claims 8
- -1 aliphatic amino acids Chemical class 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 6
- 239000002872 contrast media Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 239000002184 metal Substances 0.000 claims 5
- 230000005855 radiation Effects 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000005661 hydrophobic surface Effects 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Ornithine Chemical compound NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 3
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 claims 3
- 125000003716 cholic acid group Chemical group 0.000 claims 3
- 238000004132 cross linking Methods 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims 2
- DRAJWRKLRBNJRQ-UHFFFAOYSA-N Hydroxycarbamic acid Chemical compound ONC(O)=O DRAJWRKLRBNJRQ-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- YEYCQJVCAMFWCO-UHFFFAOYSA-N [10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] formate Chemical compound C1C=C2CC(OC=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 YEYCQJVCAMFWCO-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical compound OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 239000000412 dendrimer Substances 0.000 claims 2
- 229920000736 dendritic polymer Polymers 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 230000005660 hydrophilic surface Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229920002521 macromolecule Polymers 0.000 claims 2
- 238000002428 photodynamic therapy Methods 0.000 claims 2
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 claims 1
- JDPJOMBMWZQSCY-BYPYZUCNSA-N (2r)-2-(2-aminoethylamino)-3-sulfanylpropanoic acid Chemical compound NCCN[C@@H](CS)C(O)=O JDPJOMBMWZQSCY-BYPYZUCNSA-N 0.000 claims 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 1
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 claims 1
- JVYDLYGCSIHCMR-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)butanoic acid Chemical compound CCC(CO)(CO)C(O)=O JVYDLYGCSIHCMR-UHFFFAOYSA-N 0.000 claims 1
- UFYGCFHQAXXBCF-UHFFFAOYSA-N 2,4-dihydroxybutanoic acid Chemical compound OCCC(O)C(O)=O UFYGCFHQAXXBCF-UHFFFAOYSA-N 0.000 claims 1
- YSHBXOGJSHJCAO-UHFFFAOYSA-N 3-amino-2-(aminomethyl)-2-methylpropanoic acid Chemical compound NCC(C)(CN)C(O)=O YSHBXOGJSHJCAO-UHFFFAOYSA-N 0.000 claims 1
- IPHWMPQMASHHHM-UHFFFAOYSA-N 3-amino-2-(aminomethyl)propanoic acid Chemical compound NCC(CN)C(O)=O IPHWMPQMASHHHM-UHFFFAOYSA-N 0.000 claims 1
- ZEDMWCZZMFUPFY-UHFFFAOYSA-N 4-amino-2-(2-aminoethyl)butanoic acid Chemical compound NCCC(C(O)=O)CCN ZEDMWCZZMFUPFY-UHFFFAOYSA-N 0.000 claims 1
- RNQFIALWYREPBF-UHFFFAOYSA-N 5-amino-2-propylpentanoic acid Chemical compound CCCC(C(O)=O)CCCN RNQFIALWYREPBF-UHFFFAOYSA-N 0.000 claims 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 239000005153 Cholesterol Formate Substances 0.000 claims 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000002812 cholic acid derivative Substances 0.000 claims 1
- 150000001842 cholic acids Chemical class 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 238000007626 photothermal therapy Methods 0.000 claims 1
- 108010094020 polyglycine Proteins 0.000 claims 1
- 229920000232 polyglycine polymer Polymers 0.000 claims 1
- 108010000222 polyserine Proteins 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- CPGDBICFYAWNBO-UHFFFAOYSA-N CC(CCC(NCCOCCOCCNC)=O)=O Chemical compound CC(CCC(NCCOCCOCCNC)=O)=O CPGDBICFYAWNBO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736067P | 2012-12-12 | 2012-12-12 | |
| US61/736,067 | 2012-12-12 | ||
| US13/803,878 US9642916B2 (en) | 2012-12-12 | 2013-03-14 | Porphyrin modified telodendrimers |
| US13/803,878 | 2013-03-14 | ||
| PCT/US2013/074762 WO2014093675A1 (en) | 2012-12-12 | 2013-12-12 | Porphyrin modified telodendrimers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511222A JP2016511222A (ja) | 2016-04-14 |
| JP2016511222A5 true JP2016511222A5 (enExample) | 2017-01-26 |
| JP6585504B2 JP6585504B2 (ja) | 2019-10-02 |
Family
ID=50881159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547561A Active JP6585504B2 (ja) | 2012-12-12 | 2013-12-12 | ポルフィリン修飾されたテロデンドリマー |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9642916B2 (enExample) |
| EP (1) | EP2931290B1 (enExample) |
| JP (1) | JP6585504B2 (enExample) |
| CN (1) | CN105188717B (enExample) |
| WO (1) | WO2014093675A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9642916B2 (en) | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
| KR101421974B1 (ko) * | 2013-04-17 | 2014-07-24 | 한양대학교 산학협력단 | 그래핀 옥사이드/담즙산 또는 그의 염 코팅층을 포함하는 복합 분리막 및 그 제조방법 |
| US20180078652A1 (en) * | 2015-04-24 | 2018-03-22 | The Regents Of The University Of California | Nanoporphyrin telodendrimers for treatment of vascular abnormalities |
| WO2017031084A1 (en) * | 2015-08-14 | 2017-02-23 | The Regents Of The University Of California | Poly(vinyl alcohol) nanocarriers |
| CN105288623B (zh) * | 2015-11-19 | 2018-06-05 | 同济大学 | 一种用于肿瘤治疗的药物及其制备方法 |
| CN106853248B (zh) * | 2015-12-09 | 2020-05-05 | 首都师范大学 | 一种光热复合纳米材料及其制备方法与应用 |
| JP6889432B2 (ja) * | 2016-04-28 | 2021-06-18 | 学校法人甲南学園 | 樹脂固定ペプチド |
| JP7102005B2 (ja) * | 2016-09-15 | 2022-07-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善されたハイブリッドテロデンドリマー |
| CN110996963A (zh) * | 2017-06-16 | 2020-04-10 | 加利福尼亚大学董事会 | 活性药物成分的缀合物 |
| CN107417706B (zh) * | 2017-08-04 | 2019-07-16 | 大连理工大学 | 具有光、声敏活性的二氢卟吩青蒿琥酯结合物及其制备方法与应用 |
| US11612681B2 (en) * | 2017-09-06 | 2023-03-28 | The Research Foundation For The State University Of New York | Compositions and devices for removal of endotoxins and cytokines from fluids |
| EP3801600B1 (en) * | 2018-06-05 | 2025-04-30 | University of Mississippi Medical Center | PRODUCTION OF ELP MACROPARTICLES AND MICROPARTICLES FOR DRUG DELIVERY |
| CN113330056A (zh) * | 2018-08-31 | 2021-08-31 | 加利福尼亚大学董事会 | 基于花青的末端树枝状共聚物及其治疗癌症的用途 |
| CN109253993B (zh) * | 2018-10-25 | 2021-03-23 | 中国石油大学(华东) | 纳米荧光探针及其制备方法和应用 |
| CA3119993A1 (en) * | 2018-11-20 | 2020-05-28 | Starpharma Pty Ltd | Therapeutic dendrimer |
| EP3886912A4 (en) * | 2018-11-29 | 2023-01-04 | Starpharma Pty Limited | DENDRIMER FOR THERAPY AND IMAGING |
| CA3138176A1 (en) | 2019-04-27 | 2020-11-05 | Health Research, Inc. | Coumarin-modified androgens for the treatment of prostate cancer |
| CN110591075B (zh) * | 2019-06-28 | 2022-03-04 | 四川大学华西医院 | 一种PEG-Peptide线性-树状给药系统及其制备方法和用途 |
| CN110292633B (zh) * | 2019-08-01 | 2021-09-03 | 深圳市老年医学研究所 | 一种基于共价自组装方式构建的具有光动力学性能的纳米胶囊及其检测方法 |
| CN110804190B (zh) * | 2019-11-05 | 2021-10-29 | 东莞行渡科技有限公司 | 嵌入芳酰胺片段的亲疏水分子自组装胶束及超分子光催化组装体的制备方法 |
| US20230076792A1 (en) * | 2019-12-17 | 2023-03-09 | The Regents Of The University Of California | Sequential targeting in crosslinking nano-theranostics for treating brain tumors |
| WO2021243415A1 (en) * | 2020-06-03 | 2021-12-09 | Starpharma Pty Ltd | Therapeutic conjugates |
| CN111607101A (zh) * | 2020-06-29 | 2020-09-01 | 南京大学 | 一种具有活性氧响应性的树状大分子及其制法和用途 |
| CN114848852B (zh) * | 2021-01-20 | 2023-04-28 | 中国科学院精密测量科学与技术创新研究院 | 一种自组装石墨烯量子点纳米粒子及其制备方法及其应用 |
| CN112964683B (zh) * | 2021-02-08 | 2022-06-17 | 山西医科大学 | 叶酸修饰氮掺杂石墨烯量子点/银纳米荧光探针的制备方法和应用 |
| CN115192705B (zh) * | 2021-04-13 | 2023-10-13 | 中国科学院化学研究所 | 一种两性离子共价有机聚合物/二氧化钛纳米复合材料及其制备方法和应用 |
| CN113248753B (zh) * | 2021-05-11 | 2022-04-22 | 中南大学湘雅医院 | 一种羟基蒽醌体外循环改性膜的制备方法 |
| KR102697416B1 (ko) * | 2021-05-20 | 2024-08-21 | 성균관대학교산학협력단 | 옥살레이트계 화합물을 포함하는 초음파 기반의 항암 면역치료용 고분자 복합체 및 이의 제조방법 |
| CN114788863A (zh) * | 2022-03-16 | 2022-07-26 | 苏州深得源健康科技有限公司 | 一种制备卟啉锌纳米空心球的方法及其应用 |
| CN115518156B (zh) * | 2022-10-12 | 2023-10-10 | 西安交通大学医学院第二附属医院 | 一种响应性释放近红外光热剂的纳米复合物、制备方法及应用 |
| CN116606297B (zh) * | 2023-04-07 | 2024-11-26 | 井冈山大学 | 一类尾式苯丙氨酸卟啉衍生物的合成方法和应用 |
| CN118852184B (zh) * | 2024-09-26 | 2025-01-28 | 浙江浙能技术研究院有限公司 | 一种具有装载和靶向释放喜树碱类药物的超分子材料及其制备方法和应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| SK17422000A3 (sk) | 1998-05-20 | 2001-09-11 | The Liposome Company, Inc. | Kompozöcie ¬astöc |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| KR100396171B1 (ko) | 1998-08-10 | 2003-08-27 | 아사히 가세이 가부시키가이샤 | 염산 파수딜의 경구 서방성 제제 |
| ES2237146T3 (es) * | 1998-08-28 | 2005-07-16 | Destiny Pharma Limited | Derivados de porfirina, su uso en terapia fotodinamica y dispositivos medicos que los contienen. |
| US6365191B1 (en) | 1999-02-17 | 2002-04-02 | Dabur Research Foundation | Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof |
| JP4659937B2 (ja) | 1999-11-19 | 2011-03-30 | ナノキャリア株式会社 | コア−シェル構造のポリイオンコンプレックスミセル |
| US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
| US6638924B2 (en) | 2000-08-30 | 2003-10-28 | Pharmacyclics, Inc. | Metallotexaphyrin derivatives |
| US6797727B2 (en) | 2001-07-16 | 2004-09-28 | Transition Therapeutics Inc. | Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
| AU2002953073A0 (en) | 2002-11-21 | 2003-01-16 | Access Pharmaceuticals Australia Pty Limited | Amplification of biotin-mediated targeting |
| EP1596828B1 (en) | 2003-02-14 | 2011-12-28 | Children's Hospital & Research Center at Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| JP3953037B2 (ja) | 2004-03-10 | 2007-08-01 | 独立行政法人科学技術振興機構 | 多数の人工光合成反応中心を有する亜鉛ポルフィリンデンドリマーとピリジルナフタレンジイミドとの超分子錯体 |
| US8153111B2 (en) * | 2004-06-18 | 2012-04-10 | Ceramoptec Industries, Inc. | Photo-triggered release of active substances from dendrimer-photosensitizer complexes |
| KR100578382B1 (ko) | 2004-07-16 | 2006-05-11 | 나재운 | 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법 |
| US20060127467A1 (en) | 2004-12-14 | 2006-06-15 | Watkin Kenneth L | Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods |
| US7846893B2 (en) | 2005-02-16 | 2010-12-07 | Rutgers, The State University Of New Jersey | Drug-polymer conjugates coupled to a peptidic carrier |
| CU23556A1 (es) | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| AU2006336311B2 (en) | 2006-01-19 | 2013-01-24 | Allexcel, Inc. | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers |
| AU2007296190A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Lysine-based polymeric linkers |
| EP2087912B1 (en) | 2006-11-22 | 2017-05-10 | The University of Tokyo | Sirna carrier using disulfide-bridged polymeric micelle |
| JP5539733B2 (ja) | 2007-01-22 | 2014-07-02 | オールエクセル，インコーポレイティド | 抗ウイルス薬としての自己集合性の両親媒性高分子 |
| JP2010516328A (ja) | 2007-01-23 | 2010-05-20 | エリオ，ポール，エー | チューブ・リクライナ機構および座席 |
| WO2009123934A2 (en) | 2008-03-29 | 2009-10-08 | Emory University | Branched multifunctional nanoparticle conjugates and their use |
| WO2009155335A2 (en) | 2008-06-19 | 2009-12-23 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization |
| US9579400B2 (en) * | 2008-09-23 | 2017-02-28 | The Regents Of The University Of California | Nanocarriers for drug delivery |
| US9296988B2 (en) | 2009-06-19 | 2016-03-29 | The Regents Of The University Of California | Three-dimensional cell adhesion matrix |
| KR101793082B1 (ko) | 2009-09-24 | 2017-11-02 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 방광암 특이적 리간드 펩티드 |
| EP2488206B1 (en) | 2009-10-16 | 2018-03-21 | University Health Network (UHN) | Porphyrin nanovesicles |
| US8945513B2 (en) | 2011-03-18 | 2015-02-03 | International Business Machines Corporation | Star polymer nanoshells and methods of preparation thereof |
| WO2012158622A2 (en) | 2011-05-13 | 2012-11-22 | The Regents Of The University Of California | Reversibly crosslinked micelle systems |
| US8895055B2 (en) | 2011-12-21 | 2014-11-25 | The Regents Of The University Of California | Telodendrimer nanodiscs without apolipoprotein |
| EP2793953B1 (en) | 2011-12-21 | 2019-12-04 | The Regents of The University of California | Telodendrimers with enhanced drug delivery |
| US9642916B2 (en) | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
| US11406714B2 (en) | 2013-08-21 | 2022-08-09 | The Research Foundation For The State University Of New York | Telodendrimers and nanocarriers and methods of using same |
| US20180078652A1 (en) | 2015-04-24 | 2018-03-22 | The Regents Of The University Of California | Nanoporphyrin telodendrimers for treatment of vascular abnormalities |
| WO2018136778A1 (en) | 2017-01-19 | 2018-07-26 | The Research Foundation For The State University Of New York | Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same |
| US11612681B2 (en) | 2017-09-06 | 2023-03-28 | The Research Foundation For The State University Of New York | Compositions and devices for removal of endotoxins and cytokines from fluids |
-
2013
- 2013-03-14 US US13/803,878 patent/US9642916B2/en active Active
- 2013-12-12 JP JP2015547561A patent/JP6585504B2/ja active Active
- 2013-12-12 WO PCT/US2013/074762 patent/WO2014093675A1/en not_active Ceased
- 2013-12-12 US US14/651,860 patent/US10238750B2/en active Active
- 2013-12-12 CN CN201380072874.1A patent/CN105188717B/zh active Active
- 2013-12-12 EP EP13863207.0A patent/EP2931290B1/en active Active
-
2017
- 2017-03-24 US US15/468,916 patent/US20180036417A1/en not_active Abandoned
-
2019
- 2019-03-15 US US16/355,123 patent/US11219692B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511222A5 (enExample) | ||
| Zhang et al. | Nanoparticulation of prodrug into medicines for cancer therapy | |
| Yu et al. | Host-guest chemistry in supramolecular theranostics | |
| Robertson et al. | Gadolinium theranostics for the diagnosis and treatment of cancer | |
| Kesharwani et al. | Dendrimer as nanocarrier for drug delivery | |
| Wang et al. | Stimuli-responsive programmed specific targeting in nanomedicine | |
| Maeda | Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects | |
| Thanh et al. | Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release | |
| JP2012503603A5 (enExample) | ||
| JP6585504B2 (ja) | ポルフィリン修飾されたテロデンドリマー | |
| Mekuria et al. | PAMAM dendrimer based targeted nano-carrier for bio-imaging and therapeutic agents | |
| JP2017149960A5 (enExample) | ||
| Li et al. | Choline derivate-modified doxorubicin loaded micelle for glioma therapy | |
| Zagami et al. | Folate-decorated amphiphilic cyclodextrins as cell-targeted nanophototherapeutics | |
| Wang et al. | Design, synthesis, and biological evaluations of asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeted drug delivery | |
| Tran et al. | Heparin-folate-retinoic acid bioconjugates for targeted delivery of hydrophobic photosensitizers | |
| JP7102005B2 (ja) | 改善されたハイブリッドテロデンドリマー | |
| Thambi et al. | Recent advances in shell-sheddable nanoparticles for cancer therapy | |
| CN103044437A (zh) | 用于治疗肿瘤的两亲性缀合物纳米颗粒及制备方法、应用 | |
| Feng et al. | New strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology | |
| Nair K et al. | Folic acid conjugated δ-valerolactone-poly (ethylene glycol) based triblock copolymer as a promising carrier for targeted doxorubicin delivery | |
| Le et al. | Trend in biodegradable porous nanomaterials for a nticancer drug delivery | |
| Cheng et al. | Water-soluble single-chain polymeric nanoparticles for highly selective cancer chemotherapy | |
| Zhou et al. | Hyper-branched multifunctional carbon nanotubes carrier for targeted liver cancer therapy | |
| Sousa et al. | Analyzing PEGylation through molecular dynamics simulations |